Olaparib Improves Outcomes in BRCA-Altered Castration-Resistant Prostate Cancer

Mutations in the DNA damage repair genes BRCA 1 and BRCA2 increase a tumor’s susceptibility to treatment with poly(ADP)ribose polymerase (PARP) inhibitors. This treatment approach is standard in breast and ovarian cancers, where these mutations commonly occur. Mutations in BRCA1/2 and the DNA damage repair gene ATM occur in as many as 30% of patients […]

Read More

CDK4/6 Inhibitors Demonstrate Consistent Survival Benefit in Breast Cancer

For patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, treatment with a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor in combination with endocrine therapy is a highly effective treatment option. Three CDK4/6 inhibitors are currently approved in the United States in this setting. At the ESMO Congress 2019, final results from the MONARCH 2 […]

Read More

Postsurgical Radiotherapy Not Necessary for Prostate Cancer

For men with early-stage prostate cancer, the standard of care for many years has been radical prostatectomy followed by adjuvant radiotherapy to prevent disease recurrence. However, the benefits of radiotherapy in this setting are not well documented and can be associated with numerous toxic effects. At the ESMO Congress 2019, results from a large clinical […]

Read More

Nivolumab/Ipilimumab Associated With High Rates of Long-Term Survival in Melanoma

In the past decade, the 5-year survival rate for patients with metastatic melanoma has increased dramatically, from less than 5% with chemotherapy to 20% with ipilimumab monotherapy. More recently, the introduction of PD-1 and PD-L1 inhibitors into the care of patients with metastatic melanoma has further improved survival outcomes, particularly when used in combination with […]

Read More

Two Years of Hormone Therapy Increases Mortality in Recurrent Prostate Cancer

Treatment with antiandrogen therapy is a standard of care for men with prostate cancer receiving salvage radiotherapy following postsurgical biochemical recurrence. This standard, based in part on results from the randomized phase III RTOG 9601 trial, found that the addition of 2 years of antiandrogen therapy to postoperative radiotherapy resulted in a significant improvement in […]

Read More

SCLC

Durvalumab Improves OS for Extensive Stage Small Cell Lung Cancer

Extensive stage small cell lung cancer (SCLC) has historically been associated with limited treatment options and a poor prognosis. In recent years, immunotherapy with PD-1 and PD-L1 targeting antibodies has emerged as an effective treatment option for these patients with progressive disease. Recently, the PD-L1 inhibitor atezolizumab was approved for use in the first-line setting […]

Read More

Treatment of Early Lung Cancer With Video-Assisted Surgery

Surgical resection is a standard of care for early lung cancer. However, the most frequent surgical approach, open surgical resection, is associated with a high degree of morbidity and risk of complications. Video-assisted thoracic surgery (VATS), sometimes called ‘keyhole surgery’, is an alternative approach to surgery for lung cancer, but it is currently underutilized, particularly […]

Read More

Immunotherapy-saves-world-prIME-LINES

Encorafenib Plus Cetuximab and Binimetinib Improves OS in BRAF Mutant CRC

Approximately 10% to 15% of patients with metastatic colorectal cancer (mCRC) carry BRAF V600E mutations, which are associated with a poor prognosis and limited treatment options. Treatment with BRAF inhibitors has historically been ineffective due to multiple feedback mechanisms present in the MAP kinase pathway, leading to resistance. In other tumor types, combination of BRAF […]

Read More

Daratumumab-VTd Combo, a New Option For Transplant Eligible Myeloma

The majority of patients with newly diagnosed multiple myeloma (NDMM) are treated with induction therapy followed by autologous stem cell transplant (ASCT) and consolidation therapy. The combination of bortezomib, thalidomide, and dexamethasone (VTd) is one of the standard induction/consolidation regimens. Daratumumab, a CD38-targeting antibody, is effective as monotherapy and in combinations in relapsed or refractory […]

Read More

Lenalidomide Can Prevent Development of Symptomatic Multiple Myeloma

Smoldering multiple myeloma (SMM) is a heterogeneous disease. While observation is often sufficient for patients with low-risk disease, those with high-risk characteristics are more likely to develop symptomatic multiple myeloma (MM) and have poor outcomes. Early intervention in patients with high-risk disease may be an effective strategy to improve outcomes in this population. This was […]

Read More